Table 4.
Summary of results with different dosage at different observation points for IOAB.
| Outcomes | Number of RCTs | MD/RR | 95%CI | I2 (%) | P for I2 |
|---|---|---|---|---|---|
| Maximum Detrusor Pressure (MDP) | |||||
| 12 weeks | |||||
| BTX-A 50U VS. Placebo | 1 | 4.7 | -3.49, 12.89 | NA | NA |
| BTX-A 100U VS. Placebo | 1 | 0.2 | -7.55, 7.95 | NA | NA |
| BTX-A 150U VS. Placebo | 1 | -4.2 | -12.70, 4.30 | NA | NA |
| BTX-A 200U VS. Placebo | 1 | 5.7 | -3.28, 14.68 | NA | NA |
| BTX-A 300U VS. Placebo | 1 | 0.1 | -9.86, 10.06 | NA | NA |
| BTX-A 100U VS. 50U | 1 | -4.5 | -11.78,2.78 | NA | NA |
| BTX-A 150U VS. 50U | 1 | -8.9 | -16.98, -0.82 | NA | NA |
| BTX-A 150U VS. 100U | 1 | -4.4 | -12.03, 3.23 | NA | NA |
| BTX-A 200U VS. 50U | 1 | 1 | -7.57,9.57 | NA | NA |
| BTX-A 200U VS. 100U | 1 | 5.5 | -2.66, 13.66 | NA | NA |
| BTX-A 200U VS. 150U | 1 | 9.9 | 1.03, 18.77 | NA | NA |
| BTX-A 300U VS. 50U | 1 | -4.6 | -14.20, 5.00 | NA | NA |
| BTX-A 300U VS. 100U | 1 | -0.1 | -9.33, 9.13 | NA | NA |
| BTX-A 300U VS. 150U | 1 | 4.3 | -5.57, 14.17 | NA | NA |
| BTX-A 300U VS. 200U | 1 | -5.6 | -15.88, 4.68 | NA | NA |
| 36 weeks | |||||
| BTX-A 50U VS. Placebo | 1 | 2.6 | -8.24, 13.44 | NA | NA |
| BTX-A 100U VS. Placebo | 1 | 8 | -2.52, 18.52 | NA | NA |
| BTX-A 150U VS. Placebo | 1 | 3.4 | -7.14, 13.94 | NA | NA |
| BTX-A 200U VS. Placebo | 1 | 3.8 | -6.66, 14.26 | NA | NA |
| BTX-A 300U VS. Placebo | 1 | 8.1 | -3.15, 19.35 | NA | NA |
| BTX-A 100U VS. 50U | 1 | 5.4 | -1.62,12.42 | NA | NA |
| BTX-A 150U VS. 50U | 1 | 0.8 | -6.25, 7.85 | NA | NA |
| BTX-A 150U VS. 100U | 1 | -4.6 | -11.15, 1.95 | NA | NA |
| BTX-A 200U VS. 50U | 1 | 1.2 | -5.73,8.13 | NA | NA |
| BTX-A 200U VS. 100U | 1 | -4.2 | -10.62, 2.22 | NA | NA |
| BTX-A 200U VS. 150U | 1 | 0.4 | -6.05, 6.85 | NA | NA |
| BTX-A 300U VS. 50U | 1 | 5.5 | -2.58,13.58 | NA | NA |
| BTX-A 300U VS. 100U | 1 | 0.1 | -7.55, 7.75 | NA | NA |
| BTX-A 300U VS. 150U | 1 | 4.7 | -2.97, 12.37 | NA | NA |
| BTX-A 300U VS. 200U | 1 | 4.3 | -3.26, 11.86 | NA | NA |
| Detrusor compliance (DC) | |||||
| 12 weeks | |||||
| BTX-A 50U VS. Placebo | 1 | 65.5 | 23.24, 107.76 | NA | NA |
| BTX-A 100U VS. Placebo | 1 | 85.8 | 41.31, 130.29 | NA | NA |
| BTX-A 150U VS. Placebo | 1 | 36.4 | -8.85, 81.65 | NA | NA |
| BTX-A 200U VS. Placebo | 1 | 104.5 | 47.52, 161.48 | NA | NA |
| BTX-A 300U VS. Placebo | 1 | 75.8 | 23.42, 128.18 | NA | NA |
| BTX-A 100U VS. 50U | 1 | 20.3 | -28.92, 69.52 | NA | NA |
| Maximum Detrusor Pressure (MDP) | |||||
| BTX-A 150U VS. 100U | 1 | -49.4 | -101.21, 2.41 | NA | NA |
| BTX-A 200U VS. 50U | 1 | 39 | -21.74, 99.74 | NA | NA |
| BTX-A 200U VS. 100U | 1 | 18.7 | -43.62, 81.02 | NA | NA |
| BTX-A 200U VS. 150U | 1 | 68.1 | 5.24, 130.96 | NA | NA |
| BTX-A 300U VS. 50U | 1 | 10.3 | -46.15, 66.75 | NA | NA |
| BTX-A 300U VS. 100U | 1 | -10 | -68.14, 48.14 | NA | NA |
| BTX-A 300U VS. 150U | 1 | 39.4 | -19.32, 98.12 | NA | NA |
| BTX-A 300U VS. 200U | 1 | -28.7 | -96.87, 39.47 | NA | NA |
| 36 weeks | |||||
| BTX-A 50U VS. Placebo | 1 | 60.3 | 16.08, 104.52 | NA | NA |
| BTX-A 100U VS. Placebo | 1 | 39.3 | -6.18, 84.78 | NA | NA |
| BTX-A 150U VS. Placebo | 1 | 24.8 | -30.63, 80.23 | NA | NA |
| BTX-A 200U VS. Placebo | 1 | 64.8 | 4.24, 125.36 | NA | NA |
| BTX-A 300U VS. Placebo | 1 | 60.8 | 11.64, 109.96 | NA | NA |
| BTX-A 100U VS. 50U | 1 | -21 | -62.98, 20.98 | NA | NA |
| BTX-A 150U VS. 50U | 1 | -35.5 | -88.10, 17.10 | NA | NA |
| BTX-A 150U VS. 100U | 1 | -14.5 | -68.16, 39.16 | NA | NA |
| BTX-A 200U VS. 50U | 1 | 4.5 | -53.48, 62.48 | NA | NA |
| BTX-A 200U VS. 100U | 1 | 25.5 | -33.45, 84.45 | NA | NA |
| BTX-A 200U VS. 150U | 1 | 40 | -26.93, 106.93 | NA | NA |
| BTX-A 300U VS. 50U | 1 | 0.5 | -45.43, 46.43 | NA | NA |
| BTX-A 300U VS. 100U | 1 | 21.5 | -25.65, 68.65 | NA | NA |
| BTX-A 300U VS. 150U | 1 | 36 | -20.81, 92.81 | NA | NA |
| BTX-A 300U VS. 200U | 1 | -4 | -65.83, 57.83 | NA | NA |
| Adverse Events* | |||||
| Urinary tract infections (UTI) | |||||
| BTX-A 50U VS. Placebo | 2 | 1.95 | 0.96, 3.98 | 0 | 0.675 |
| BTX-A 100U VS. Placebo | 5 | 2.55 | 2.09, 3.12 | 0 | 0.656 |
| BTX-A 150U VS. Placebo | 2 | 2.36 | 1.19, 4.68 | 0 | 0.355 |
| BTX-A 200U VS. Placebo | 2 | 2.68 | 1.46, 4.93 | 0 | 0.634 |
| BTX-A 300U VS. Placebo | 1 | 2.12 | 0.98, 4.58 | NA | NA |
| BTX-A 100U VS. 50U | 2 | 0.97 | 0.59, 1.59 | 18.5 | 0.268 |
| BTX-A 150U VS. 50U | 2 | 1.24 | 0.78, 1.98 | 0 | 0.594 |
| BTX-A 150U VS. 100U | 2 | 1.29 | 0.81, 2.05 | 0 | 0.443 |
| BTX-A 200U VS. 50U | 1 | 1.42 | 0.89, 2.25 | NA | NA |
| BTX-A 200U VS. 100U | 3 | 1.44 | 0.94, 2.20 | 0 | 0.685 |
| BTX-A 200U VS. 150U | 1 | 1.09 | 0.72, 1.67 | NA | NA |
| BTX-A 300U VS. 50U | 1 | 1.02 | 0.61, 1.71 | NA | NA |
| BTX-A 300U VS. 100U | 1 | 0.95 | 0.57, 1.57 | NA | NA |
| BTX-A 300U VS. 150U | 1 | 0.79 | 0.49, 1.27 | NA | NA |
| BTX-A 300U VS. 200U | 1 | 0.72 | 0.45, 1.14 | NA | NA |
| Urinary retention | |||||
| BTX-A 50U VS. Placebo | 1 | 3.84 | 0.47, 31.67 | NA | NA |
| BTX-A 100U VS. Placebo | 4 | 13.99 | 5.71, 34.30 | 0 | 0.946 |
| BTX-A 150U VS. Placebo | 1 | 12.04 | 1.65, 87.85 | NA | NA |
| BTX-A 200U VS. Placebo | 1 | 9.92 | 1.34, 73.29 | NA | NA |
| BTX-A 300U VS. Placebo | 1 | 10.95 | 1.50, 80.00 | NA | NA |
| BTX-A 100U VS. 50U | 1 | 2.04 | 0.74, 5.57 | NA | NA |
| BTX-A 150U VS. 50U | 1 | 3.14 | 1.22, 8.09 | NA | NA |
| BTX-A 150U VS. 100U | 1 | 1.54 | 0.75, 3.15 | NA | NA |
| BTX-A 200U VS. 50U | 1 | 2.58 | 0.98, 6.84 | NA | NA |
| BTX-A 200U VS. 100U | 2 | 1.34 | 0.66, 2.72 | 0 | 0.707 |
| BTX-A 200U VS. 150U | 1 | 0.82 | 0.42, 1.60 | NA | NA |
| BTX-A 300U VS. 50U | 1 | 2.85 | 1.10, 7.38 | NA | NA |
| BTX-A 300U VS. 100U | 1 | 1.4 | 0.68, 2.88 | NA | NA |
| BTX-A 300U VS. 150U | 1 | 0.91 | 0.48, 1.71 | NA | NA |
| BTX-A 300U VS. 200U | 1 | 1.1 | 0.56, 2.16 | NA | NA |
| PVR-related catheterization | |||||
| BTX-A 50U VS. Placebo | 2 | 1.06 | 0.26, 4.27 | 56.5 | 0.129 |
| BTX-A 100U VS. Placebo | 2 | 2.31 | 0.72, 7.37 | 58.2 | 0.122 |
| BTX-A 150U VS. Placebo | 2 | 2.4 | 0.79, 7.30 | 83.8 | 0.013 |
| BTX-A 200U VS. Placebo | 3 | 15.74 | 3.13, 79.31 | 0 | 0.985 |
| BTX-A 300U VS. Placebo | 1 | 14.93 | 0.89, 249.52 | NA | NA |
| BTX-A 100U VS. 50U | 2 | 2.28 | 0.73, 7.10 | 0 | 0.767 |
| BTX-A 150U VS. 50U | 2 | 2.89 | 0.98, 8.48 | 7.5 | 0.298 |
| BTX-A 150U VS. 100U | 3 | 1.22 | 0.57, 2.63 | 25.7 | 0.26 |
| BTX-A 200U VS. 50U | 1 | 3.95 | 1.17, 13.37 | NA | NA |
| BTX-A 200U VS. 100U | 1 | 1.94 | 0.77, 4.86 | NA | NA |
| BTX-A 200U VS. 150U | 1 | 1.06 | 0.49, 2.77 | NA | NA |
| BTX-A 300U VS. 50U | 1 | 3.05 | 0.87, 10.69 | NA | NA |
| BTX-A 300U VS. 100U | 1 | 1.5 | 0.57, 3.93 | NA | NA |
| BTX-A 300U VS. 150U | 1 | 0.82 | 0.36, 1.85 | NA | NA |
| BTX-A 300U VS. 200U | 1 | 0.77 | 0.35, 1.71 | NA | NA |
| Hematuria | |||||
| BTX-A 100U VS. Placebo | 2 | 1.38 | 0.78, 2.42 | 73.7 | 0.051 |
NA, Not available.